

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**WUXI BIOLOGICS (CAYMAN) INC.**

**藥明生物技術有限公司\***

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2269)**

## **INSIDE INFORMATION**

### **2023 BUSINESS UPDATE**

This announcement is made by WuXi Biologics (Cayman) Inc. (the “**Company**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The Company will convene a business update meeting today at which it will conduct a presentation containing financial and other information regarding the Company’s business operations (the “**Presentation**”). To ensure that all shareholders and potential investors of the Company have equal and timely access to the information pertaining to the Company and its operations, the Company has published the full copy of the Presentation on its website ([www.wuxibiologics.com](http://www.wuxibiologics.com)) under the section headed “Investors”. Shareholders and potential investors of the Company are reminded that the Presentation may contain forward-looking statements, which are, by their nature, subject to significant risks and uncertainties, and any estimate and future proposals stated in the Presentation are based on certain assumptions and estimates and on management’s judgements in light of currently available information only.

**Shareholders and potential investors of the Company are advised not to place undue reliance on the information contained in the Presentation and to exercise caution when dealing in the securities of the Company.**

By order of the Board  
**WuXi Biologics (Cayman) Inc.**  
**Dr. Ge Li**  
*Chairman*

Hong Kong, December 4, 2023

*As at the date of this announcement, the Board comprises Dr. Zhisheng Chen and Dr. Weichang Zhou as executive Directors; Dr. Ge Li, Mr. Yibing Wu and Mr. Yanling Cao as non-executive Directors; and Mr. William Robert Keller, Mr. Kenneth Walton Hitchner III, Mr. Jackson Peter Tai and Dr. Jue Chen as independent non-executive Directors.*

\* *For identification purpose only*